Publisher： Adis International
ISSN： 1173-8324
Source： Inpharma, Vol.1, Iss.1308, 2001-01, pp. : 15-15
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Which gemcitabine dosage schedule best in NSCLC?
Inpharma, Vol. 1, Iss. 1479, 2005-01 ,pp. :
Access to resources
Recommend
Gemcitabine plus vinorelbine superior in NSCLC
Inpharma, Vol. 1, Iss. 1251, 2000-01 ,pp. :
RRM1-based tailored chemotherapy for NSCLC?
Inpharma, Vol. 1, Iss. 1432-1433, 2004-01 ,pp. :
Time to consider placebo effect in QOL studies in NSCLC?
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 327, 2001-01 ,pp. :
Polymorphisms: prognostic factors in advanced NSCLC?
Inpharma, Vol. 1, Iss. 1454, 2004-01 ,pp. :